8:00
Malignancy I – Biliary, Liver and Pancreas
Chairmen: Cristian Gheorghe, Alina Tantau, Sergiu Cazacu
[08.00-08.15] Trend in epidemiology and natural history
Sergiu Cazacu
[08.15-08.35] Advances in transabdominal ultrasound
Larisa Sandulescu
[08.35-08.55] Advances in endoscopic ultrasound
Alina Tantau
[08.55-09.15] Advances in ERCP
Cristian Gheorghe
[09.15-09.30] Advances in imaging diagnosis - CT & MRI
Ioana Gheonea
9:30
The HCV infection in 2022 and the road to elimination
Chairmen: Liana Gheorghe, Anca Trifan, Ion Rogoveanu
[09.30-09.45] Screening strategies in Romania and worldwide
Cora Pop
[09.45-09.55] Artificial Intelligence in HCV Screening
Costin Streba
[09.55-10.15] Livero 2 SOUTH Project - update
Liana Gheorghe
[10.15-10.35] Livero 2 EAST Project - update
Anca Trifan
[10.35-10.50] New protocols and therapies in Romania
Ion Rogoveanu
[10.50-11.00] Innovative therapies worldwide
Supported by Genesis
Lucian Negreanu
11:30
Pharma symposia
Chairmen: Dan Gheonea, Mircea Diculescu
[11.30-11.45] Innergy
Emerging role of intestinal microbiota in NAFLD/NASH
Ion Rogoveanu
11:45
Abbvie Symposia
The power of new DAA's: Maviret Next Gen in HCV
Chairman: Dan Gheonea
[11.45-11.55] Power of new DAA's: Maviret the value of short therapy in and post - pandemic era
Liana Gheorghe
[11.55-12.05] MAVIRET: Next Generation in HCV
Marcel Tantau
[12.05-12.15] Treatment strategies for all types of HCV patients
Mircea Diculescu
[12.15-12.25] Benefits of short treatment for patients, physicians, and the healthcare system
Eugen Dumitru
[12.25-12.35] The therapeutic management & simplification as a driver for achieving elimination of HCV
Anca Trifan
[12.35-12.45] Biessen-Pharma
The wave leaves, energy remains: Astenor supports specific metabolic processes
Gindrovel Dumitra
[12.45-13.00] AlfaSigma
The role of Rifaximinum in IBS
Paul Mitrut
[13.00-13.15] Gilead
Multiple questions, a single response: Epclusa
Ion Rogoveanu
[13.15-13.30] Sunwave Pharma
Progresses in therapy of intestinal functional disorders
Lucian Negreanu
[13.30-13.45] Bayer
Multi-target treatment in functional digestive and motility disorders
Sergiu Cazacu
14:30
New data in IBD – Romania and worldwideSupported by Janssen
Chairmen: Lucian Negreanu, Adrian Goldiș, Bogdan Mateescu
[14.30-14.50] Ulcerative colitis – progressive disease
Catalina Mihai
[14.50-15.05] Therapy stratifying in UC
Adrian Goldis
[15.05-15.20] New therapies in IBD. Real world data
Lucian Negreanu
[15.20-15.35] Safety of new therapies in IBD
Bogdan Mateescu
[15.35-16.00] Patients national registry in Romania and developed tools
Dan Gheonea, Mircea Diculescu
16:30
Malignancy II – Gastric and colorectal cancer
Chairmen: Daniela Dobru, Eugen Dumitru, Mircea Mănuc
[16.30-16.45] Rules for an efficient colorectal cancer screening
Daniela Dobru
[16.45-17.00] ROCCAS I & II Projects Concepts
Mircea Manuc
[17.00-17.30] Regional Update ROCCAS II
Dan Gheonea, Mircea Manuc, Eugen Dumitru
[17.30-17.45] Gastric cancer in Romania and Republic of Moldavia - Trends in natural history
Sevastita Iordache
[17.45-18.00] Early diagnosis and endoscopic treatment
Viorel Istrate, Nicolae Bodrug
18:00
Malignancy III – Neuroendocrine tumors
Chairmen: Mircea Diculescu, Catalina Poiana, Michael Schenker
[18.00-18.20] Digestive system – diffuse endocrine gland
Mircea Diculescu
[18.20-18.40] Neuroendocrine tumors – endocrinologist perspective
Catalina Poiana
[18.40-19.00] Diagnosis and staging of neuroendocrine tumors
Michael Schenker
[19.00-19.20] Any news in systemic treatment of NET?
Adina Croitoru
[19.20-19.30] Conclusions and perspective
Mircea Diculescu, Catalina Poiana